MoonLake Immunotherapeutics (MLTX) stock
MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.79−0.46 (-4.09%)
Close on Nov 18, 2026Market cap $918.30MP/E –Yield –
MoonLake Immunotherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
MoonLake Immunotherapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$225.18M. For fiscal 2025 it was -$196.04M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$196.04M | – |
| FY2024 | Dec 31, 2024 | -$117.11M | – |
| FY2023 | Dec 31, 2023 | -$43.06M | – |
| FY2022 | Dec 31, 2022 | -$55.91M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$55.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$66.29M | – |
| Q4 FY2025 | Dec 31, 2025 | -$58.79M | – |
| Q3 FY2025 | Sep 30, 2025 | -$44.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$54.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$38.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$48.65M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.41M | – |
| Q2 FY2024 | Jun 30, 2024 | -$27.89M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.63M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.60M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.20M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.03M | – |
See a number that looks wrong?